AboutContact usRSS
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
Google’s $32 billion acquisition of Wiz draws antitrust attention
2
Navan to file confidentially for IPO, betting on market reopening
3
Andreessen Horowitz targets elite IDF alumni for startup accelerator
4
Intel to cut jobs at Kiryat Gat fab, says it must “position our business for the future”
5
Intel to begin foundry layoffs in July, but uncertainty hangs over Israel amid wartime reality
More news

Immunotherapy

9 stories about Immunotherapy
רחובות החדשה זירת הנדל"ן

Cancer Immunotherapy Startup NeoTX Raises $45 Million

20.02.20|Adi Pick
NeoTX uses STR to bind genetically engineered bacteria to tumor cells and simultaneously activate the antibacterial response of distant immune cells
מריוס נכט 2

Allogenic Immunotherapy Company Adicet Bio Raises $80 Million

02.10.19|Meir Orbach
Founded by Israeli chemist Aya Jakobovits, Adicet develops universal immune cell therapies based on gamma delta T cells to treat different forms of cancer
שי נוביק יו"ר אנלייבקס

CEO of Nasdaq-Listed Cell Immunotherapy Company Enlivex Steps Down

02.10.19|Tzally Greenberg
Enlivex develops cell-based treatments for life-threatening immune and inflammatory conditions, such as graft versus host disease, a post bone marrow transplant complication
נאסדק

Compugen Falls 17% on Employee Cuts Announcement

27.02.19|Lilach Baumer
The Nasdaq-listed cancer immunotherapy company published its fourth quarter and full year results for 2018 Tuesday
ענת כהן-דייג מנכ"לית קומפיוג'ן

Bristol-Myers Squibb Invests $12 Million in Israeli Immunotherapy Company Compugen

12.10.18|Dror Reich
The investment is part of a clinical trial collaboration for a treatment that combines Compugen’s investigational antibody with an immune checkpoint inhibitor from Bristol-Myers Squibb
ענת כהן-דייג מנכ"לית קומפיוג'ן

AstraZeneca Signs Deal with Cancer Immunotherapy Company Compugen

03.04.18|Lilach Baumer
The deal has the potential to be worth over $200 million for Nasdaq-listed Compugen
default image

Kite Pharma’s Cancer Drug Gets Regulatory Nod

19.10.17|Lilach Baumer
The cancer-treatment company, bought by Gilead Science in August for $11.9 billion, will sell one treatment course of the drug for $373,000
מוסף שבועי 14.9.17 פרופ' גידי גרוס

Kite Pharma Sale Triggers Scientist Quarrel

02.10.17|Zohar Shahar Levy
Zelig Eshhar who patented the company’s core technology is now being sued by his former PhD student and current pharma entrepreneur
default image

Cell Immunotherapy Company Raises $8 Million

24.09.17|Lilach Baumer
Enlivex Therapeutics Ltd. is a clinical-stage company specializing in autoimmune and inflammatory conditions